Abivax

Abivax SA (Euronext: ABVX) is a French biotechnology company headquartered in Paris, France.[1] The company is developing treatments for patients with inflammatory diseases, viral infections and cancer.[2]

Abivax
Traded asEuronext Paris
ISIN code: FR0012333284
ISINFR0012333284 
IndustryBiotechnology, Pharmaceutical
Founded2013 (2013) in France
Headquarters
Paris
,
France
Websiteabivax.com

Pipeline

ABX464 for Ulcerative Colitis

ABX464 is an oral, first-in-class, small molecule that has demonstrated safety and profound anti-inflammatory activity in preclinical trials and in a completed Phase 2a proof-of-concept study to treat lesions in ulcerative colitis. When evaluated in a Phase 2a Proof-of-Concept study, ABX464-101,[3] ABX464 demonstrated both safety and statistically significant efficacy based on both clinical and endoscopic endpoints with 3.2-fold improvement in clinical remission rate and 4.5-fold in mucosal healing compared to placebo. Based on the positive results from the ABX464-101 study, Abivax is in the process of initiating a Phase 2b study of ABX464 in ulcerative colitis in the first quarter of 2019. The company is also conducting ABX464-102,[4] a 12-month open-label study focusing on patients from study ABX464-101.

ABX464 for HIV

ABX464 is an oral, first-in-class, small molecule inhibiting HIV replication through an entirely new mechanism of action, and has completed three Phase 2a clinical trials.[5] In two Phase 2a clinical trials, ABX464-004 and ABX464-005, ABX464 demonstrated up to 50% reduction of HIV-DNA in peripheral blood mononuclear cells after 28 days of combination treatment with anti-retroviral therapy.

  1. "Abivax SA". www.bloomberg.com. Retrieved 2018-11-29.
  2. "Abivax posts ulcerative colitis data, commits to phase 2b | FierceBiotech". www.fiercebiotech.com. Retrieved 2018-11-29.
  3. "ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-01-15.
  4. "Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-01-15.
  5. "ABX464 Clinical Trials, Side Effects". AIDSinfo. Retrieved 2019-01-30.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.